Demonstrates enhanced efficacy and optimized safety for topical androgen receptor antagonists in androgenetic alopecia, suggesting a new treatment approach.
achieved comparable efficacy to 0.5% pyrilutamide with accelerated response kinetics (14-day vs 21-day onset) and preserved safety. This dual metabolic inactivation strategy successfully reconciles therapeutic potency with a low risk of systemic toxicity, providing a paradigm for next-generation topical AR antagonist development.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: